Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
Journal of Experimental & Clinical Cancer Research : CR|July 18, 2003
HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parametersA M Cianciulli, F Guadagni, R Marzano, et al.
Journal of Cancer Research and Clinical Oncology|January 12, 2001
Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapyM Mottolese, M Benevolo, G Del Monte, et al.
Gynecologic Oncology|April 1, 1994
Noninvasive monitoring of ovarian cancer: improved results using CT with intraperitoneal contrast combined with immunocytologyS Giunta, I Venturo, M Mottolese, et al.
Oncogenesis|September 2, 2014
Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancerR Lattanzio, R Ghasemi, F Brancati, et al.
International Journal of Cancer|February 7, 2001
Prognostic relevance of altered Fas (CD95)-system in human breast cancerM Mottolese, S Buglioni, C Bracalenti, et al.
American Journal of Hematology|August 1, 1987
Two murine monoclonal antibodies to peripheral blood monocyte differentiation antigens discriminate within M5 acute non-lymphoid leukemia (ANLL) cellsM Lopez, G De Rossi, L Santoro, et al.
International Journal of Cancer|January 15, 1990
Use of monoclonal antibodies to human breast-tumor-associated antigens in the diagnosis of fine-needle aspirates of breast nodules: results of a multicenter studyP G Natali, M Mottolese, R P Donnorso, et al.
Gynecologic Oncology|April 26, 2002
Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancerG Ferrandina, F O Ranelletti, L Lauriola, et al.
British Journal of Cancer|November 26, 1999
p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancerG Ferrandina, A Fagotti, M G Salerno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2010
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabineG Metro, J Foglietta, M Russillo, et al.
Pageof 10